as on October 16, 2025 at 1:29 am IST
Day's Low
Day's High
5.56%
Downside
0.33%
Upside
52 Week's Low
52 Week's High
22.86%
Downside
73.33%
Upside
Check Ultragenyx Pharmaceutical Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$3.1B
EPS (TTM)
-5.0583
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-8.97
Industry PE ratio
8.355964912280701
PEG Ratio
-0.24
EBITDA
-469.6M
Revenue (TTM)
610.2M
Profit Margin
-87.34%
Return On Equity TTM
102285500.00%
Track how Ultragenyx Pharmaceutical Inc. P/E has moved over time to understand its valuation trends.
Ultragenyx Pharmaceutical Inc. in the last 5 years
Lowest (-43.63x)
March 31, 2021
Today (-8.97x)
October 16, 2025
Industry (8.36x)
October 16, 2025
Highest (-3.89x)
December 31, 2022
Today’s Price to Earnings Ratio: -8.97x
Compare market cap, revenue, PE, and other key metrics of Ultragenyx Pharmaceutical Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $3.1B | -63.65% | -8.97 | -87.34% | |
BUY | $61.5B | 223.43% | -505.15 | -12.96% | |
NA | $37.1B | NA | NA | -3.89% | |
BUY | $105.7B | 87.04% | 28.99 | 31.86% | |
BUY | $59.6B | -3.89% | 14.07 | 31.37% |
The Ultragenyx Pharmaceutical Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Ultragenyx Pharmaceutical Inc. investment value today
Current value as on today
₹62,636
Returns
Returns from Ultragenyx Pharmaceutical Inc. Stock
Dollar Returns*
₹4,647 (+4.65%)
Based on 27 analysts
88.89%
Buy
11.11%
Hold
0.00%
Sell
Based on 27 analysts, 88.89% of analysts recommend a 'BUY' rating for Ultragenyx Pharmaceutical Inc.. Average target price of $86.05
Get share price movements and forecasts by analysts on Ultragenyx Pharmaceutical Inc..
What analysts predicted
61.12%UPSIDE
Target Price
$86.05
Current Price
$33.46
Analyzed by
27 Analysts
Target
$86.05
Ultragenyx Pharmaceutical Inc. target price $86.05, a slight upside of 61.12% compared to current price of $33.46. According to 27 analysts rating.
Search interest for Ultragenyx Pharmaceutical Inc. Stock has increased by 41% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:41% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 7 days, RARE stock has moved up by 5.6%
Profit Spike
Netprofit is up for the last 2 quarters, -151.08M → -114.95M (in $), with an average increase of 31.4% per quarter
Revenue Rich
Revenue is up for the last 2 quarters, 139.29M → 166.49M (in $), with an average increase of 16.3% per quarter
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 153.5% return, outperforming this stock by 163.3%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 56.5% return, outperforming this stock by 98.6%
Organisation | Ultragenyx Pharmaceutical Inc. |
Headquarters | 60 Leveroni Court, Novato, CA, United States, 94949 |
Industry | Health Technology |
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Howard Horn | Executive VP of Corporate Strategy & CFO |
Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences |
Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP |
Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs |
Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director |
Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer |
Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer |
Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP |
Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations |
Ultragenyx Pharmaceutical Inc. share price today is $33.46 as on at the close of the market. Ultragenyx Pharmaceutical Inc. share today touched a day high of $33.57 and a low of $31.6.
Ultragenyx Pharmaceutical Inc. share touched a 52 week high of $58 on and a 52 week low of $25.81 on . Ultragenyx Pharmaceutical Inc. stock price today i.e. is closed at $33.46,which is 42.31% down from its 52 week high and 29.64% up from its 52 week low.
Ultragenyx Pharmaceutical Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Ultragenyx Pharmaceutical Inc. (RARE) shares with as little as ₹87.83 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.30 in Ultragenyx Pharmaceutical Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Ultragenyx Pharmaceutical Inc. share’s latest price of $33.46 as on October 16, 2025 at 1:29 am IST, you will get 0.2989 shares of Ultragenyx Pharmaceutical Inc.. Learn more about
fractional shares .
Ultragenyx Pharmaceutical Inc. stock has given -63.65% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?